TITLE

FDA APPROVES ANDROGEL TO TREAT MALE TESTOSTERONE DEFICIENCY

PUB. DATE
April 2000
SOURCE
Worldwide Biotech;Apr2000, Vol. 12 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that the United States Food and Drug Administration has approved a testosterone replacement gel manufactured by Unimed Pharmaceuticals for hypogonadism.
ACCESSION #
3004621

 

Related Articles

  • Unimed's Androgel NDA Filed With FDA for 12-Month Review.  // Biotech Business;Sep99, Vol. 12 Issue 9, p1 

    Reports that Unimed Pharmaceuticals, Inc. has announced that its New Drug Application (NDA) for Androgel testosterone gel has been filed with the United States Food and Drug Administration. Purpose of Androgel (TM); Symptoms of hypogonadism; Drugs marketed by Unimed Pharmaceuticals, Inc.

  • FDA, Repros meeting: no new safety trials due for Androxal. Osborne, Randy // BioWorld Today;2/10/2014, Vol. 25 Issue 27, p1 

    The article reports on the meeting held between Repros Therapeutics Inc. and the U.S. Food and Drug Administration (FDA). The FDA agreed in the meeting that Repros Therapeutics Inc. will not need new safety tests before submitting the new drug application (NDA) for its Androxal (enclomiphene)...

  • THERE'S THE RUB. Pfeiffer, Naomi // Drug Topics;3/20/2000, Vol. 144 Issue 6, p31 

    Reports on the approval by the United States Food and Drug Administration of AndroGel, a testosterone gel for treating hypogonadism developed by Unimed Pharmaceuticals. Application of the gel; Marketing of AndroGel; Results of the clinical trial of the drug.

  • Product Preview.  // Urology Times;Sep2010, Vol. 38 Issue 10, p43 

    No abstract available.

  • FDA approves testosterone gel for hypogonadism.  // Endocrine Today;Jan2011, Vol. 9 Issue 1, p31 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve a clear, odorless gel for the treatment of hypogonadism.

  • Discovery Pipeline. Ritter, Amy // BioPharm International;Apr2012, Vol. 25 Issue 4, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the first allogenic cell-based therapy, called GINTUIT, which uses cells unrelated to the patient to create the therapeutic.

  • FDA research uncovers clues on serious diseases.  // FDA Consumer;Mar/Apr98, Vol. 32 Issue 2, p4 

    Presents the results of two studies that may change the way some life-threatening illnesses are treated published by US Food and Drug Administration. Name of the publications in which the results of the study have been published; Medical conditions in which this discovery may have potential...

  • Unapproved But Not Always Unavailable. Thompson, Larry // FDA Consumer;Jan/Feb2000, Vol. 34 Issue 1, p8 

    Discusses the issue of the availability of experimental treatments for seriously ill patients in the United States. Percent of drugs in testing that will ultimately be approved; Incorrect perception of the public about the Food and Drug Administration; Pros and cons of experimental treatments;...

  • Treatment Approved for Acute Bleeding Disorder.  // Clarendon Enterprise (TX);2/19/2009, Vol. 20 Issue 8, p10 

    The article reports that the U.S. Food and Drug Administration has approved the drug RiaSTAP to treat the rare bleeding disorder Congenital Fibrinogen Deficiency.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics